Use of purine derivatives for the manufacture of a medicament

1. A method for the treatment of patients affected by chronic lymphoid leukemia, comprising at least one step of administration to said patients of at least one compound

of following formula Id:

or one of its pharmaceutically acceptable salts or esters,

or of following formula Ie:

or one of its pharmaceutically acceptable salts or esters,

or of an oxalate salt of a compound of following formula If:

or of following formula Ig:

or one of the pharmaceutically acceptable salts,

or of following formula Ih:

or of following formula Ib:

or one of its pharmaceutically acceptable salts or esters,

or of an ester of compounds of following formulae II-1 or II-3:

2. The method according to claim 1 , wherein the pharmaceutically acceptable salt is an oxalate or tartrate or hydrochloride or fumarate salt.

3. The method according to claim 1 , wherein the at least one compound is the compound of following formula Ib:

or one of its pharmaceutically acceptable salts or esters.

4. The method according to claim 3 , wherein the at least one compound is the oxalate salt of the compound of formula Ib.

5. A method for the treatment of patients affected by polycystic kidney disease, comprising at least one step of administration to said patients of at least one compound of following formula I:

in which:

X is N,

Y is CH 3 or OH, and

Z is H or CH 3 ,

or one of its pharmaceutically acceptable salts or esters.

6. The method according to claim 5 , wherein the pharmaceutically acceptable salt is an oxalate or tartrate or hydrochloride or fumarate salt.

7. The method according to claim 5 , wherein the at least one compound is the compound of formula I in which X is N and Y is OH.

8. The method according to claim 5 , wherein the at least one compound is the compound of formula I in which X is N, Y is CH 3 and Z is H, of following formula Ia:

or one of its pharmaceutically acceptable salts or esters,

or of formula I in which X is N, Y is OH and Z is H, of following formula Id:

or one of its pharmaceutically acceptable salts or esters,

or of formula I in which X is N, Y is CH 3 and Z is CH 3 , of following formula Ie:

or one of its pharmaceutically acceptable salts or esters,

or an oxalate salt of the compound of formula I in which X is N, Y is CH 3 and Z is CH 3 , of following formula If:

or has the following formula Ig:

or one of the pharmaceutically acceptable salts,

or has the following formula Ih:

9. The method according to claim 5 , wherein the at least one compound is the compound of formula I in which X is N, Y is CH 3 and Z is H, of (S) absolute configuration, of following formula Ib:

or one of its pharmaceutically acceptable salts or esters.

10. The method according to claim 5 , wherein the at least one compound is an ester chosen from the compounds of following formulae II-1 to II-4:

11. The compound of following formula Ib:

or one of its salts or esters.

12. The compound of following formula Id:

or one of its salts or esters, or

of following formulae Ie:

or the salts or esters of the latter, or

of following formula If:

or

of following formula Ig:

or one of its salts or esters, or

of following formula Ih:

13. A compound, wherein it has the following formulae II-1 to II-4: